Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailRecordati CEO sees 'substantial opportunity' in Sanofi drug purchaseRob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune disorder drug, Enjaymo.
Persons:
Rob Koremans
Organizations:
Sanofi